Lupin jumped 12% to Rs 651.70 at 14:30 IST on BSE after its unit Lupin Pharmaceuticals Inc received tentative approval from US Food and Drug Administration for ramipril capsules.
The stock hit a high of Rs 653.70 and a low of Rs 575 so far during the day. The stock had a 52-week high of Rs 745 on
The company’s current equity is Rs 82.07 crore. Face value per share is Rs 10.
The current price of Rs 651.70 discounts its Q4 March 2008 annualised EPS of Rs 37.35, by a PE multiple of 17.25.
Ramipril capsules used for treating cardiovascular disease and high blood pressure.
In April 2008, Lupin’s subsidiary in Japan, Kyowa Pharmaceutical Industry Co, received approvals from the country's ministry of health and labour welfare for 10 products.
Lupin’s net profit declined 44% to Rs 76.64 crore on 19.6% increase in net sales to Rs 619.57 crore in Q4 March 2008 over Q4 March 2007.
Lupin is engaged in manufacturing active pharmaceutical ingredients and formulations
No comments:
Post a Comment